Approximately 300 million people worldwide are persistently infected with the hepatitis B virus and are at risk of developing hepatocellular carcinoma and liver cirrhosis, which can progress to end-stage liver disease. Despite the effectiveness of the current vaccination policy, the prevalence of the disease remains high, and the burden for health services is considerable. The currently available antiviral strategies are either poorly effective or only effective for non-curative suppression of viral replication. Recent efforts have been focused on improving the cure rate for chronic hepatitis B and developing strategies to eliminate infected cells. Several approaches are under evaluation, and these include targeting the virus at different stages of its life cycle and boosting the antiviral immune response. This article reviews these latest approaches and comments on their feasibility and potential translation into clinical applications.

Chronic hepatitis B: Are we close to a cure? / E, Loggi; Vitale, Giovanni; Conti, Fabio; Bernardi, Mauro; Andreone, Pietro. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 47:(2015), pp. 836-841. [10.1016/j.dld.2015.05.019]

Chronic hepatitis B: Are we close to a cure?

Mauro Bernardi;Pietro Andreone .
2015

Abstract

Approximately 300 million people worldwide are persistently infected with the hepatitis B virus and are at risk of developing hepatocellular carcinoma and liver cirrhosis, which can progress to end-stage liver disease. Despite the effectiveness of the current vaccination policy, the prevalence of the disease remains high, and the burden for health services is considerable. The currently available antiviral strategies are either poorly effective or only effective for non-curative suppression of viral replication. Recent efforts have been focused on improving the cure rate for chronic hepatitis B and developing strategies to eliminate infected cells. Several approaches are under evaluation, and these include targeting the virus at different stages of its life cycle and boosting the antiviral immune response. This article reviews these latest approaches and comments on their feasibility and potential translation into clinical applications.
47
836
841
Chronic hepatitis B: Are we close to a cure? / E, Loggi; Vitale, Giovanni; Conti, Fabio; Bernardi, Mauro; Andreone, Pietro. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 47:(2015), pp. 836-841. [10.1016/j.dld.2015.05.019]
E, Loggi; Vitale, Giovanni; Conti, Fabio; Bernardi, Mauro; Andreone, Pietro
File in questo prodotto:
File Dimensione Formato  
CHB cure.pdf

non disponibili

Dimensione 618.64 kB
Formato Adobe PDF
618.64 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1237302
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact